MFN: Pfizer Productive Talks with Trump Admin

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump administration, Pfizer CEO Albert Bourla, Ph.D.—who has frequently touted his strong relationship with the president—is accentuating the positive.